HIV-infected women with central adiposity and HIV-@ RNA < @ HIV-@ RNA copies/mL continued their thymidine-sparing nucleoside reverse transcriptase inhibitor ( NRTI ) backbone and were randomized to switch to open-label RAL at week @ ( immediate ) or @ ( delayed ) .